Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis

• Published in: PloS one 2024-10, Vol.19 (10), p.e0309034
• Main Authors: Evans, Denise, Hirasen, Kamban, Ramushu, Clive, Long, Lawrence, Sinanovic, Edina, Conradie, Francesca, Howell, Pauline, Padanilam, Xavier, Ferreira, Hannetjie, Variaiva, Ebrahim, Rajaram, Shakira, Gupta, Aastha, Juneja, Sandeep, Ndjeka, Norbert
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Analysis; Antitubercular Agents - economics; Antitubercular Agents - therapeutic use; Care and treatment; Clinical trials; Cost analysis; Cost assessments; Cost benefit analysis; Cost effectiveness; Cost-Effectiveness Analysis; Diarylquinolines - economics; Diarylquinolines - therapeutic use; Dietary supplements; Drug resistance; Drug resistance in microorganisms; Drug Therapy, Combination - economics; Economic aspects; Evaluation; Female; Health Care Costs - statistics & numerical data; Health care expenditures; Health services; Humans; Interviews; Linezolid; Linezolid - economics; Linezolid - therapeutic use; Male; Medical care, Cost of; Medical economics; Medical records; Medical research; Medicine and Health Sciences; Medicine, Experimental; Middle Aged; Multidrug resistance; Nitroimidazoles; Operations research; Patient outcomes; Patients; People and places; Rifampin; Social Sciences; South Africa; Sputum; Standard of care; Surveys; Tuberculosis; Tuberculosis, Multidrug-Resistant - drug therapy; Tuberculosis, Multidrug-Resistant - economics; Young Adult
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0309034

Drug-resistant (DR) tuberculosis (TB) is typically characterized by resistance to a single or combination of first- and/or second-line anti-TB agents and commonly includes rifampicin-resistant (RR)-TB, multidrug-resistant (MDR)-TB, pre-extensively drug-resistant (pre-XDR)-TB and XDR-TB. Historically, all variations of DR-TB required treatment with second-line drugs which are less effective and more toxic than first-line options, have a longer treatment duration and are more expensive to both patients and providers. The World Health Organization (WHO) now recommends a new second-line 3-drug 6-month all-oral regimen consisting of bedaquiline, pretomanid, and linezolid referred to as BPaL. We estimate patient and provider costs of DR-TB treatment with BPaL compared to the current standard of care in South Africa. In coordination with South Africa's BPaL clinical access programme (CAP) we conducted an economic evaluation of A) patient costs through a cross-sectional patient cost survey and B) provider costs through a bottom-up costing analysis consisting of a retrospective medical record review (patient resource-use) and top-down financial record review (fixed/shared costs such as overhead). Across both costing perspectives, we compare costs of 1) BPaL, to current standard of care options including the 2) 9-11-month standard short oral regimen (SSOR) and 3) 18-21-month standard long oral regimen (SLOR). Eligible patients included those ≥14 years old with confirmed sputum pulmonary RR/MDR-TB, pre-XDR or XDR-TB. All costs are reported in 2022 United States Dollar (US$). A total of 72 patients were enrolled and completed the patient cost survey (41.7% on BPaL, 16.7% on the SSOR and 41.7% on the SLOR). Mean on-treatment patient costs were lowest among those on BPaL ($56.6) and increased four-fold among those on the SSOR ($228.1) and SLOR ($224.7). Direct medical patient costs were negligible across all treatment regimens, while direct non-medical patient and guardian costs for travel, food and nutritional supplementation accounted for the largest proportion of total costs ($54.6, $227.8 and $224.3 for BPaL, the SSOR and SLOR respectively). In assessing provider costs, a total of 112 medical records were reviewed (37.5%, 41.1% and 21.4% on BPaL, the SSOR and SLOR respectively). Total provider costs for producing a favorable treatment outcome (cured/completed treatment) were similar among those on BPaL ($4,948.7 per patient) and the SSOR ($4,905.6 per patient) with